PRNewsWire
18 Mar 2026, 13:00 UTC · 26w ago
Verdict
Headline takes no side. We score CORT −1.00 across three claims — strongly bearish.
−1.00strongly bearish
More negative than 96% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA expressed concerns regarding the adequacy of Corcept's relacorilant effectiveness program and the design of the GRACE study.
More negative than 99% of claims this week
The FDA warned Corcept to expect significant issues with the review if the company proceeded to submit the New Drug Application (NDA) for relacorilant.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 98% of claims this week
A class action securities lawsuit has been filed alleging Corcept made false or misleading statements regarding its interactions with the FDA and expectations for relacorilant's approval.
More negative than 86% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company is facing a class action securities lawsuit alleging fraud regarding FDA interactions and trial designs.
More negative than 92% of ticker scores this week
The company experienced a significant single-session share price decline of nearly 18% following its second quarter report.
More negative than 89% of ticker scores this week
The company is the subject of a pending investigation into discrepancies between reported adjusted earnings and actual losses.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
7h ago
+239.5%
Price is moving against the score
$113.76 vs $33.51 close before publication (Mar 17) · not market-adjusted
CORT chart →